Apr. 20 at 7:43 PM
$ASRT Talkin bout THIS SAYS IT ALL.. LET'S GIVE AWAY THE FARM:
Garda Therapeutics agreed to acquire Assertio Holdings in a roughly US
$120 million deal, offering US
$18 per share in cash plus a non tradeable contingent value right linked to future Sprix milestones, with total cash consideration of US
$125.1 million.
The Garda transaction, including the tender offer and expected delisting, received unanimous approval from both Boards and is subject to customary closing conditions. These include a majority of outstanding shares being tendered and Assertio having at least US
$115 million of closing net cash, while the company issued full year 2026 GAAP net product sales guidance of US
$110.0 million to US
$125.0 million.
